Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Pulmonary Hypertension, July 2017

Free Subscription


Abstracts

Retrieve all available abstracts of the following 106 articles:
HTML format


 

Single Articles

  1. TORRICELLI E, Occhipinti M, Lavorini F, Cresci C, et al
    Pulmonary hypertension nosography: are all patients classifiable?
    Intern Emerg Med. 2017 Jun 30. doi: 10.1007/s11739-017-1700.
    Abstract    



  2. EMA R, Sugiura T, Kawata N, Tanabe N, et al
    The dilatation of main pulmonary artery and right ventricle observed by enhanced chest computed tomography predict poor outcome in inoperable chronic thromboembolic pulmonary hypertension.
    Eur J Radiol. 2017 Jun 12. pii: S0720-048X(17)30245.
    Abstract    

    Abstract available

  3. PANAGIOTOU M, Johnson MK, Louvaris Z, Baker JS, et al
    A study of clinical and physiological relations of daily physical activity in precapillary pulmonary hypertension.
    J Appl Physiol (1985). 2017 Jun 29:jap.00986.2016.
    Abstract    

    Abstract available

  4. ARASZKIEWICZ A, Jankiewicz S, Janus M, Lanocha M, et al
    Optical coherence tomography reveals the mechanisms of balloon pulmonary angioplasty in inoperable chronic thromboembolic pulmonary hypertension.
    Cardiol J. 2017;24:334-335.
    Abstract    



  5. O'LEARY JM, Assad TR, Xu M, Birdwell KA, et al
    Pulmonary hypertension in patients with chronic kidney disease: invasive hemodynamic etiology and outcomes.
    Pulm Circ. 2017 Jun 29:2045893217716108. doi: 10.1177/2045893217716108.
    Abstract    

    Abstract available

  6. RODRIGUES MP, Vissoci CM, Rosa SP, Negreiros SBC, et al
    24-Hour Hypoxia and Pulmonary Hypertension in Patients with Idiopathic Pulmonary Fibrosis.
    Open Respir Med J. 2017;11:10-16.
    Abstract    

    Abstract available

  7. GHIGNA MR, Mooi WJ, Grunberg K
    Pulmonary hypertensive vasculopathy in parenchymal lung diseases and/or hypoxia: Number 1 in the Series "Pathology for the clinician" Edited by Peter Dorfmuller and Alberto Cavazza.
    Eur Respir Rev. 2017;26.
    Abstract    

    Abstract available

  8. BALEGADDE AV, Vijan V, Thachathodiyl R
    A Case Series of Young Patients with Completely Reversed Severe Pulmonary Hypertension.
    J Clin Diagn Res. 2017;11:OR04-OR05.
    Abstract    

    Abstract available

  9. PARK BY, Chung SH
    Treprostinil for persistent pulmonary hypertension of the newborn, with early onset sepsis in preterm infant: 2 Case reports.
    Medicine (Baltimore). 2017;96:e7303.
    Abstract    

    Abstract available

  10. JIANG R, Wu C, Pudasaini B, Wang L, et al
    A novel scoring index by Doppler echocardiography for predicting severe pulmonary hypertension due to chronic lung diseases: a cross-sectional diagnostic accuracy study.
    Int J Chron Obstruct Pulmon Dis. 2017;12:1741-1751.
    Abstract    

    Abstract available

  11. ROUSHDY A, Adel W
    Independent predictors of developing pulmonary hypertension in heart failure with reduced versus preserved ejection fraction.
    J Saudi Heart Assoc. 2017;29:185-194.
    Abstract    

    Abstract available

  12. PICCININO C, Giubertoni A, Zanaboni J, Gravellone M, et al
    Incremental value of right atrial strain for early diagnosis of hemodynamic deterioration in pulmonary hypertension: a new noninvasive tool for a more comprehensive diagnostic paradigma.
    J Cardiovasc Med (Hagerstown). 2017 Jun 24. doi: 10.2459/JCM.0000000000000525.
    Abstract    

    Abstract available

  13. LUO DL, Zhang CJ, Huang YG, Huang T, et al
    [Serum uric acid is associated with disease severity and an important predictor for clinical outcome in patients with pulmonary hypertension].
    Zhonghua Xin Xue Guan Bing Za Zhi. 2017;45:496-500.
    Abstract    

    Abstract available

  14. YIN J, You S, Liu H, Chen L, et al
    Role of P2X7R in the development and progression of pulmonary hypertension.
    Respir Res. 2017;18:127.
    Abstract    

    Abstract available

  15. HONORATO PEREZ J
    Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review.
    Expert Rev Clin Pharmacol. 2017;10:753-762.
    Abstract    

    Abstract available

  16. SALIOU G, Vraka I, Teglas JP, Senat MV, et al
    "Pseudo-feeders" on fetal MRI predict outcome in vein of Galen malformations.
    Ann Neurol. 2017 Jan 11. doi: 10.1002/ana.24873.
    Abstract    

    Abstract available

  17. NAVAS TEJEDOR P, Tenorio Castano J, Palomino Doza J, Arias Lajara P, et al
    An homozygous mutation in KCNK3 is associated with an aggressive form of hereditary pulmonary arterial hypertension.
    Clin Genet. 2017;91:453-457.
    Abstract    

    Abstract available

  18. MOURADIAN GC, Gaurav R, Pugliese S, El Kasmi K, et al
    Superoxide Dismutase 3 R213G Single-Nucleotide Polymorphism Blocks Murine Bleomycin-Induced Fibrosis and Promotes Resolution of Inflammation.
    Am J Respir Cell Mol Biol. 2017;56:362-371.
    Abstract    

    Abstract available

  19. KANG BY, Park K, Kleinhenz JM, Murphy TC, et al
    Peroxisome Proliferator-Activated Receptor gamma Regulates the V-Ets Avian Erythroblastosis Virus E26 Oncogene Homolog 1/microRNA-27a Axis to Reduce Endothelin-1 and Endothelial Dysfunction in the Sickle Cell Mouse Lung.
    Am J Respir Cell Mol Biol. 2017;56:131-144.
    Abstract    

    Abstract available

  20. DA COSTA JUNIOR AA, Ota-Arakaki JS, Ramos RP, Uellendahl M, et al
    Diagnostic and prognostic value of right ventricular strain in patients with pulmonary arterial hypertension and relatively preserved functional capacity studied with echocardiography and magnetic resonance.
    Int J Cardiovasc Imaging. 2017;33:39-46.
    Abstract    

    Abstract available

  21. LIU H, Yin T, Yan W, Si R, et al
    Dysregulation of microRNA-214 and PTEN contributes to the pathogenesis of hypoxic pulmonary hypertension.
    Int J Chron Obstruct Pulmon Dis. 2017;12:1781-1791.
    Abstract    

    Abstract available

  22. FULTON DJR, Li X, Bordan Z, Haigh S, et al
    Reactive Oxygen and Nitrogen Species in the Development of Pulmonary Hypertension.
    Antioxidants (Basel). 2017;6.
    Abstract    

    Abstract available

  23. MIAO R, Wang Y, Wan J, Leng D, et al
    Microarray expression profile of circular RNAs in chronic thromboembolic pulmonary hypertension.
    Medicine (Baltimore). 2017;96:e7354.
    Abstract    

    Abstract available

  24. RASHIDI F, Sate H, Faraji E, Tahsini Tekantapeh S, et al
    Thyrotoxicosis presenting as exertional dyspnea and pulmonary hypertension: Case report and review of literature.
    SAGE Open Med Case Rep. 2017;5:2050313X17715584.
    Abstract    

    Abstract available

  25. SINGH I, Mikita G, Green D, Risquez C, et al
    Pulmonary extra-medullary hematopoiesis and pulmonary hypertension from underlying polycythemia vera: a case series.
    Pulm Circ. 2017;7:261-267.
    Abstract    

    Abstract available

  26. HSU S, Brusca SB, Rhodes PS, Kolb TM, et al
    Use of thermodilution cardiac output overestimates diagnoses of exercise-induced pulmonary hypertension.
    Pulm Circ. 2017;7:253-255.
    Abstract    

    Abstract available

  27. FRUMP AL, Albrecht ME, McClintick JN, Lahm T, et al
    Estrogen receptor-dependent attenuation of hypoxia-induced changes in the lung genome of pulmonary hypertension rats.
    Pulm Circ. 2017;7:232-243.
    Abstract    

    Abstract available

  28. LUO N, Craig D, Ilkayeva O, Muehlbauer M, et al
    Plasma acylcarnitines are associated with pulmonary hypertension.
    Pulm Circ. 2017;7:211-218.
    Abstract    

    Abstract available

  29. PAN M, Han Y, Si R, Guo R, et al
    Hypoxia-induced pulmonary hypertension in type 2 diabetic mice.
    Pulm Circ. 2017;7:175-185.
    Abstract    

    Abstract available

  30. ROTHMAN A, Wiencek RG, Davidson S, Evans WN, et al
    Challenges in the development of chronic pulmonary hypertension models in large animals.
    Pulm Circ. 2017;7:156-166.
    Abstract    

    Abstract available

  31. PRINS KW, Duval S, Markowitz J, Pritzker M, et al
    Chronic use of PAH-specific therapy in World Health Organization Group III Pulmonary Hypertension: a systematic review and meta-analysis.
    Pulm Circ. 2017;7:145-155.
    Abstract    

    Abstract available

  32. BAJWA AA, Shujaat A, Patel M, Thomas C, et al
    The safety and tolerability of inhaled treprostinil in patients with pulmonary hypertension and chronic obstructive pulmonary disease.
    Pulm Circ. 2017;7:82-88.
    Abstract    

    Abstract available

  33. RICHTER MJ, Grimminger J, Kruger B, Ghofrani HA, et al
    Effects of exercise training on pulmonary hemodynamics, functional capacity and inflammation in pulmonary hypertension.
    Pulm Circ. 2017;7:20-37.
    Abstract    

    Abstract available

  34. BEGHETTI M, Rudzinski A, Zhang M
    Efficacy and safety of oral sildenafil in children with Down syndrome and pulmonary hypertension.
    BMC Cardiovasc Disord. 2017;17:177.
    Abstract    

    Abstract available

  35. TSUBOI Y, Tanaka H, Nishio R, Sawa T, et al
    Associations of Exercise Tolerance With Hemodynamic Parameters for Pulmonary Arterial Hypertension and for Chronic Thromboembolic Pulmonary Hypertension.
    J Cardiopulm Rehabil Prev. 2017 Jun 30. doi: 10.1097/HCR.0000000000000257.
    Abstract    

    Abstract available

  36. PUJOL-LOPEZ M, San Antonio R, Flores-Umanzor EJ, Guasch E, et al
    A rare cause of severe mitral stenosis and reversible pulmonary hypertension.
    Echocardiography. 2017 Jul 3. doi: 10.1111/echo.13586.
    Abstract    

    Abstract available

  37. KLECZYNSKI P, Dziewierz A, Wiktorowicz A, Bagienski M, et al
    Prognostic value of tricuspid regurgitation velocity and probability of pulmonary hypertension in patients undergoing transcatheter aortic valve implantation.
    Int J Cardiovasc Imaging. 2017 Jul 1. doi: 10.1007/s10554-017-1210.
    Abstract    

    Abstract available

  38. MAHER TM, Dejonckheere F, Nathan SD
    Survival in Idiopathic Pulmonary Fibrosis: Perspectives from Pulmonary Arterial Hypertension.
    J Manag Care Spec Pharm. 2017;23.
    Abstract    

    Abstract available

  39. EICHSTAEDT CA, Song J, Viales RR, Pan Z, et al
    First identification of Kruppel-like factor 2 mutation in heritable pulmonary arterial hypertension.
    Clin Sci (Lond). 2017;131:689-698.
    Abstract    

    Abstract available

  40. THAO C, Shorr AF, Woods C
    Non-infectious pulmonary disorders in HIV.
    Expert Rev Respir Med. 2017;11:209-220.
    Abstract    

    Abstract available

  41. TRAN TA, Kramer B, Shin YJ, Vallar P, et al
    Discovery of 2-(((1r,4r)-4-(((4-Chlorophenyl)(phenyl)carbamoyl)oxy)methyl)cyclohexyl)methoxy)a cetate (Ralinepag): An Orally Active Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension.
    J Med Chem. 2017;60:913-927.
    Abstract    

    Abstract available

  42. RAIN S, Andersen S, Najafi A, Gammelgaard Schultz J, et al
    Right Ventricular Myocardial Stiffness in Experimental Pulmonary Arterial Hypertension: Relative Contribution of Fibrosis and Myofibril Stiffness.
    Circ Heart Fail. 2016;9.
    Abstract    

    Abstract available

  43. SHANG X, Xiao S, Dong N, Lu R, et al
    Assessing right ventricular function in pulmonary hypertension patients and the correlation with the New York Heart Association (NYHA) classification.
    Oncotarget. 2017 Jul 5. doi: 10.18632/oncotarget.19026.
    Abstract    

    Abstract available

  44. FFRENCH-O'CARROLL R, Biancardi B, Tujjar O
    Malar rash with pulmonary hypertension and chronic obstructive pulmonary disease.
    BMJ Case Rep. 2017;2017.
    Abstract    



  45. YAMAMOTO K, Tanabe N, Suda R, Sasaki A, et al
    Riociguat for patients with chronic thromboembolic pulmonary hypertension: Usefulness of transitioning from phosphodiesterase type 5 inhibitor.
    Respir Investig. 2017;55:270-275.
    Abstract    

    Abstract available

  46. SAGHEB S, Sepidarkish M, Mohseni SO, Movahedian A, et al
    Red Cell Distribution Width as a Predictor of Persistent Pulmonary Hypertension of the Newborn.
    Am J Perinatol. 2017 Jul 13. doi: 10.1055/s-0037-1604246.
    Abstract    



  47. HUTSON S, Baerg J, Deming D, St Peter SD, et al
    High Prevalence of Pulmonary Hypertension Complicates the Care of Infants with Omphalocele.
    Neonatology. 2017;112:281-286.
    Abstract    

    Abstract available

  48. SUGIMOTO K, Nakazato K, Sakamoto N, Yamaki T, et al
    Pulmonary Artery Diameter Predicts Lung Injury After Balloon Pulmonary Angioplasty in Patients With Chronic Thromboembolic Pulmonary Hypertension.
    Int Heart J. 2017 Jul 13. doi: 10.1536.
    Abstract    

    Abstract available

  49. BARNWAL NK, Umbarkar SR, Sarkar MS, Dias RJ, et al
    Randomized comparative study of intravenous infusion of three different fixed doses of milrinone in pediatric patients with pulmonary hypertension undergoing open heart surgery.
    Ann Card Anaesth. 2017;20:318-322.
    Abstract    

    Abstract available

  50. CORREALE M, Zicchino S, Monaco I, Di Biase M, et al
    Angiotensin-converting enzyme inhibitors, angiotensin II receptors antagonists, beta-blockers and ivabradine as supportive therapy in pulmonary hypertension: Drug safety and tolerability.
    Eur J Intern Med. 2017 Jul 9. pii: S0953-6205(17)30284.
    Abstract    



  51. VYAS-READ S, Kanaan U, Shankar P, Stremming J, et al
    Early characteristics of infants with pulmonary hypertension in a referral neonatal intensive care unit.
    BMC Pediatr. 2017;17:163.
    Abstract    

    Abstract available

  52. ARASZKIEWICZ A, Jankiewicz S, Mularek-Kubzdela T, Lesiak M, et al
    Stepwise optimisation of balloon pulmonary angioplasty in a patient with severe non-operable chronic thromboembolic pulmonary hypertension.
    EuroIntervention. 2017 Jul 11. pii: EIJ-D-17-00382. doi: 10.4244/EIJ-D-17-00382.
    Abstract    



  53. LEI S, Tang D, Xu N, Wu S, et al
    [Investigation and analysis for current situation and pathogenesis relevant to pulmonary hypertension].
    Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2017;42:641-646.
    Abstract    

    Abstract available

  54. COLLUM SD, Chen NY, Hernandez AM, Hanmandlu A, et al
    Inhibition of Hyaluronan Synthesis Attenuates Pulmonary Hypertension Associated with Lung Fibrosis.
    Br J Pharmacol. 2017 Jul 8. doi: 10.1111/bph.13947.
    Abstract    

    Abstract available

  55. YU L, Tu Y, Jia X, Fang K, et al
    Resveratrol Protects Against Pulmonary Arterial Hypertension in Rats via Activation of Silent Information Regulator 1.
    Cell Physiol Biochem. 2017;42:55-67.
    Abstract    

    Abstract available

  56. HOOD KY, Mair KM, Harvey AP, Montezano AC, et al
    Serotonin Signaling Through the 5-HT1B Receptor and NADPH Oxidase 1 in Pulmonary Arterial Hypertension.
    Arterioscler Thromb Vasc Biol. 2017;37:1361-1370.
    Abstract    

    Abstract available

  57. MOISEEVA OM, Rudakova AV
    [Pharmacoeconomic aspects of macitentan in the therapy of pulmonary arterial hypertension].
    Ter Arkh. 2017;89:72-77.
    Abstract    

    Abstract available

  58. TAN X, Juan FG, Shah AQ
    Involvement of endothelial progenitor cells in the formation of plexiform lesions in broiler chickens: possible role of local immune/inflammatory response.
    J Zhejiang Univ Sci B. 2017;18:59-69.
    Abstract    

    Abstract available

  59. ROWCLIFF K, de Waal K, Mohamed AL, Chaudhari T, et al
    Noradrenaline in preterm infants with cardiovascular compromise.
    Eur J Pediatr. 2016.
    Abstract    

    Abstract available

  60. PAGNAMENTA A, Azzola A, Beghetti M, Lador F, et al
    Invasive haemodynamic evaluation of the pulmonary circulation in pulmonary hypertension.
    Swiss Med Wkly. 2017;147:w14445.
    Abstract    

    Abstract available

  61. PORTEOUS MK, Lee JC, Lederer DJ, Palmer SM, et al
    Clinical Risk Factors and Prognostic Model for Primary Graft Dysfunction after Lung Transplantation in Patients with Pulmonary Hypertension.
    Ann Am Thorac Soc. 2017 Jul 18. doi: 10.1513/AnnalsATS.201610.
    Abstract    

    Abstract available

  62. THEODORAKI K, Thanopoulos A, Rellia P, Leontiadis E, et al
    A retrospective comparison of inhaled milrinone and iloprost in post-bypass pulmonary hypertension.
    Heart Vessels. 2017 Jul 17. doi: 10.1007/s00380-017-1023.
    Abstract    

    Abstract available

  63. WU B, Jiang J, Gui M, Liu L, et al
    Serum-Free Thyroxine Levels Were Associated with Pulmonary Hypertension and Pulmonary Artery Systolic Pressure in Euthyroid Patients with Coronary Artery Disease.
    Int J Endocrinol. 2017;2017:4832608.
    Abstract    

    Abstract available

  64. AKAGI S
    Novel Predictor of Lung Injury After Balloon Pulmonary Angioplasty in Patients With Chronic Thromboembolic Pulmonary Hypertension.
    Int Heart J. 2017 Jul 14. doi: 10.1536.
    Abstract    



  65. MEDREK SK, Sharafkhaneh A, Spiegelman AM, Kak A, et al
    Admission for COPD Exacerbation Is Associated with the Clinical Diagnosis of Pulmonary Hypertension: Results from a Retrospective Longitudinal Study of a Veteran Population.
    COPD. 2017 Jul 17:1-6. doi: 10.1080/15412555.2017.1336209.
    Abstract    

    Abstract available

  66. MURPHY LA, Russell N, Bianco D, Nakamura RK, et al
    Retrospective evaluation of pimobendan and sildenafil therapy for severe pulmonary hypertension due to lung disease and hypoxia in 28 dogs (2007-2013).
    Vet Med Sci. 2017;3:99-106.
    Abstract    

    Abstract available

  67. CALIN A, Mateescu AD, Rosca M, Beladan CC, et al
    Left atrial dysfunction as a determinant of pulmonary hypertension in patients with severe aortic stenosis and preserved left ventricular ejection fraction.
    Int J Cardiovasc Imaging. 2017 Jul 15. doi: 10.1007/s10554-017-1211.
    Abstract    

    Abstract available

  68. ZHANG Z, Zhang L, Sun C, Kong F, et al
    Baicalin attenuates monocrotaline-induced pulmonary hypertension through bone morphogenetic protein signaling pathway.
    Oncotarget. 2017 Jun 28. doi: 10.18632/oncotarget.18825.
    Abstract    

    Abstract available

  69. CIURZYNSKI M, Kurzyna M, Kopec G, Blaszczak P, et al
    [A statement the Polish Cardiac Society Working Group on Pulmonary Circulation on screening for CTEPH patients after acute pulmonary embolism].
    Kardiol Pol. 2017;75:620-627.
    Abstract    

    Abstract available

  70. VAIDYA B, Pangallo M, Ruffenach G, Cunningham CM, et al
    Advances in treatment of pulmonary arterial hypertension: patent review.
    Expert Opin Ther Pat. 2017;27:907-918.
    Abstract    

    Abstract available

  71. DAI Z, Zhao YY
    Discovery of a murine model of clinical PAH: Mission impossible?
    Trends Cardiovasc Med. 2017;27:229-236.
    Abstract    

    Abstract available

  72. GABRIELLI L, Ocaranza MP, Sitges M, Kanacri A, et al
    Acute effect of iloprost inhalation on right atrial function and ventricular dyssynchrony in patients with pulmonary artery hypertension.
    Echocardiography. 2017;34:53-60.
    Abstract    

    Abstract available

  73. SHLOBIN OA, Baughman RP
    Sarcoidosis-Associated Pulmonary Hypertension.
    Semin Respir Crit Care Med. 2017;38:450-462.
    Abstract    



  74. DUTTA P, Gomez D, Gladwin MT
    Do BRD(4)S of a Feather Flock Together? How an Inflammation-Driven Epigenetic Regulator May Link Pulmonary Hypertension and Coronary Artery Disease.
    Arterioscler Thromb Vasc Biol. 2017;37:1428-1430.
    Abstract    



  75. VORSELAARS V, Velthuis S, van Gent M, Westermann C, et al
    Pulmonary Hypertension in a Large Cohort with Hereditary Hemorrhagic Telangiectasia.
    Respiration. 2017 Jul 26. doi: 10.1159/000458447.
    Abstract    

    Abstract available

  76. HIRANO ACG, Targueta EP, Ferraz de Campos FP, Martines JADS, et al
    Severe pulmonary hypertension due to combined pulmonary fibrosis and emphysema: another cause of death among smokers.
    Autops Case Rep. 2017;7:15-26.
    Abstract    

    Abstract available

  77. EGOM EE, Feridooni T, Pharithi RB, Khan B, et al
    A natriuretic peptides clearance receptor's agonist reduces pulmonary artery pressures and enhances cardiac performance in preclinical models: New hope for patients with pulmonary hypertension due to left ventricular heart failure.
    Biomed Pharmacother. 2017;93:1144-1150.
    Abstract    

    Abstract available

  78. KLAASSEN SHC, Liu LCY, Hummel YM, Damman K, et al
    Clinical and Hemodynamic Correlates and Prognostic Value of VE/VCO2 Slope in Patients with Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension.
    J Card Fail. 2017 Jul 20. pii: S1071-9164(17)30616.
    Abstract    

    Abstract available

  79. MANEENIL G, Thatrimontrichai A, Janjindamai W, Dissaneevate S, et al
    Effect of bosentan therapy in persistent pulmonary hypertension of the newborn.
    Pediatr Neonatol. 2017 Jul 11. pii: S1875-9572(17)30410.
    Abstract    

    Abstract available

  80. ACOSTA S, Puelz C, Riviere B, Penny DJ, et al
    Cardiovascular mechanics in the early stages of pulmonary hypertension: a computational study.
    Biomech Model Mechanobiol. 2017 Jul 21. doi: 10.1007/s10237-017-0940.
    Abstract    

    Abstract available

  81. NIELSEN EA, Okumura K, Sun M, Hjortdal VE, et al
    Regional septal hinge-point injury contributes to adverse biventricular interactions in pulmonary hypertension.
    Physiol Rep. 2017;5.
    Abstract    

    Abstract available

  82. MUSUMECI MB, Mastromarino V, Casenghi M, Tini G, et al
    Pulmonary hypertension and clinical correlates in hypertrophic cardiomyopathy.
    Int J Cardiol. 2017 Jul 14. pii: S0167-5273(17)30943.
    Abstract    

    Abstract available

  83. HILL NS, Rahaghi FF, Sood N, Frey R, et al
    Individual dose adjustment of riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Respir Med. 2017;129:124-129.
    Abstract    

    Abstract available

  84. GILBERT G, Courtois A, Dubois M, Cussac LA, et al
    T-type voltage gated calcium channels are involved in endothelium-dependent relaxation of mice pulmonary artery.
    Biochem Pharmacol. 2017;138:61-72.
    Abstract    

    Abstract available

  85. XU M, Xu M, Han L, Yuan C, et al
    Role for Functional SOD2 Polymorphism in Pulmonary Arterial Hypertension in a Chinese Population.
    Int J Environ Res Public Health. 2017;14.
    Abstract    

    Abstract available

  86. UTSUNOMIYA H, Itabashi Y, Kobayashi S, Rader F, et al
    Effect of Percutaneous Edge-to-Edge Repair on Mitral Valve Area and Its Association With Pulmonary Hypertension and Outcomes.
    Am J Cardiol. 2017 May 30. pii: S0002-9149(17)30872.
    Abstract    

    Abstract available

  87. PALAU-CABALLERO G, Walmsley J, Van Empel V, Lumens J, et al
    Why septal motion is a marker of right ventricular failure in pulmonary arterial hypertension: mechanistic analysis using a computer model.
    Am J Physiol Heart Circ Physiol. 2017;312:H691-H700.
    Abstract    

    Abstract available

  88. NAGY BM, Nagaraj C, Meinitzer A, Sharma N, et al
    Importance of kynurenine in pulmonary hypertension.
    Am J Physiol Lung Cell Mol Physiol. 2017 Jul 13:ajplung.00517.2016.
    Abstract    

    Abstract available

  89. SA S, Gu M, Chappell J, Shao NY, et al
    Induced Pluripotent Stem Cell Model of Pulmonary Arterial Hypertension Reveals Novel Gene Expression and Patient Specificity.
    Am J Respir Crit Care Med. 2017;195:930-941.
    Abstract    

    Abstract available

  90. MWANSA H, Bilchick KC, Parker AM, Harding W, et al
    Decreased pulmonary arterial proportional pulse pressure is associated with increased mortality in group 1 pulmonary hypertension.
    Clin Cardiol. 2017 Jul 10. doi: 10.1002/clc.22752.
    Abstract    

    Abstract available

  91. JOHANNES J, Berlin DA, Patel P, Schenck EJ, et al
    A Technique of Awake Bronchoscopic Endotracheal Intubation for Respiratory Failure in Patients With Right Heart Failure and Pulmonary Hypertension.
    Crit Care Med. 2017 Jul 4. doi: 10.1097/CCM.0000000000002586.
    Abstract    

    Abstract available

  92. GIRERD B, Lau E, Montani D, Humbert M, et al
    Genetics of pulmonary hypertension in the clinic.
    Curr Opin Pulm Med. 2017 Jun 28. doi: 10.1097/MCP.0000000000000414.
    Abstract    

    Abstract available

  93. BOGAARD HJ
    Hypoxic pulmonary vasoconstriction in COPD-associated pulmonary hypertension: been there, done that?
    Eur Respir J. 2017;50.
    Abstract    



  94. GERHARDT F, Dumitrescu D, Gartner C, Beccard R, et al
    Oscillatory whole-body vibration improves exercise capacity and physical performance in pulmonary arterial hypertension: a randomised clinical study.
    Heart. 2017;103:592-598.
    Abstract    

    Abstract available

  95. BELLOFIORE A, Dinges E, Naeije R, Mkrdichian H, et al
    Reduced haemodynamic coupling and exercise are associated with vascular stiffening in pulmonary arterial hypertension.
    Heart. 2017;103:421-427.
    Abstract    

    Abstract available

  96. LADOUCEUR M, Benoit L, Radojevic J, Basquin A, et al
    Pregnancy outcomes in patients with pulmonary arterial hypertension associated with congenital heart disease.
    Heart. 2017;103:287-292.
    Abstract    

    Abstract available

  97. MENTIAS A, Patel K, Patel H, Gillinov AM, et al
    Effect of Pulmonary Vascular Pressures on Long-Term Outcome in Patients With Primary Mitral Regurgitation.
    J Am Coll Cardiol. 2016;67:2952-61.
    Abstract    

    Abstract available

  98. ABDELKARIM I, Althouse AD, Thoma FW, Lee JS, et al
    The Importance of Invasive Hemodynamics for Pulmonary Hypertension Screening in TAVR Patients.
    J Am Coll Cardiol. 2017;70:510-511.
    Abstract    



  99. GODINAS L, Sattler C, Lau EM, Jais X, et al
    Dead-space ventilation is linked to exercise capacity and survival in distal chronic thromboembolic pulmonary hypertension.
    J Heart Lung Transplant. 2017 May 22. pii: S1053-2498(17)31805.
    Abstract    

    Abstract available

  100. LANKEIT M, Krieg V, Hobohm L, Kolmel S, et al
    Pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension.
    J Heart Lung Transplant. 2017 Jul 1. pii: S1053-2498(17)31877.
    Abstract    

    Abstract available

  101. FODERARO AE, Baird GL, Bazargan-Lari A, Morrissey PE, et al
    Echocardiographic Pulmonary Hypertension Predicts Post-transplantation Renal Allograft Failure.
    Transplant Proc. 2017;49:1256-1261.
    Abstract    

    Abstract available

  102. TANAKA H, Kataoka M, Isobe S, Yamamoto T, et al
    Therapeutic impact of dietary vitamin D supplementation for preventing right ventricular remodeling and improving survival in pulmonary hypertension.
    PLoS One. 2017;12:e0180615.
    Abstract    

    Abstract available

  103. FARHA S, Hu B, Comhair S, Zein J, et al
    Mitochondrial Haplogroups and Risk of Pulmonary Arterial Hypertension.
    PLoS One. 2016;11:e0156042.
    Abstract    

    Abstract available

  104. SAHOO S, Meijles DN, Al Ghouleh I, Tandon M, et al
    MEF2C-MYOCD and Leiomodin1 Suppression by miRNA-214 Promotes Smooth Muscle Cell Phenotype Switching in Pulmonary Arterial Hypertension.
    PLoS One. 2016;11:e0153780.
    Abstract    

    Abstract available

  105. WU Y, Adi D, Long M, Wang J, et al
    4-Phenylbutyric Acid Induces Protection against Pulmonary Arterial Hypertension in Rats.
    PLoS One. 2016;11:e0157538.
    Abstract    

    Abstract available

  106. ROSE JA, Wanner N, Cheong HI, Queisser K, et al
    Flow Cytometric Quantification of Peripheral Blood Cell beta-Adrenergic Receptor Density and Urinary Endothelial Cell-Derived Microparticles in Pulmonary Arterial Hypertension.
    PLoS One. 2016;11:e0156940.
    Abstract    

    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Pulmonary Hypertension is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;